Full Coverage

Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous...

                   
yahoo.com
May 22, 2008
        
Story Timeline:  196 days

COLLEGEVILLE, Pa. & TARRYTOWN, N.Y.----Wyeth Pharmaceuticals, a division of Wyeth , and Progenics Pharmaceuticals, Inc. , today announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR™ . [read full story]                    

Add Comment
Latest article on this story:

Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous...

 webwire.com May 23, 2008
First article on this story:

Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous...

 earthtimes.org May 22, 2008
Selected publications with coverage of this story:
redorbit.com medicalnewstoday.com yahoo.com earthtimes.org drugs.com pharmiweb.co.uk tmcnet.com webwire.com
RELATED
Found 6 documents:
                   

Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous...

webwire.com
May 23, 2008
        

WEBWIRE – Friday, May 23, 2008 Collegeville, Pa., and Tarrytown, N.Y. — Wyeth Pharmaceuticals, a division of Wyeth , and Progenics Pharmaceuticals, Inc. , today announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR™...

                   

Wyeth And Progenics Announce Preliminary Clinical Trial Results For RELISTOR Oral And Intravenous...

medicalnewstoday.com
May 23, 2008
        

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR(TM) (methylnaltrexone bromide).

Market Review: Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral...

tmcnet.com
May 23, 2008
        

Streetinvesting.com has now resumed our progressive Wyeth (NYSE:WYE) as it fell down $0.31 on below average volume early trading Thursday, May 22, 2008. Wyeth Pharmaceuticals, a division of Wyeth and Progenics Pharmaceuticals, Inc. announced preliminary results from two clinical trials conducted...

                   

Wyeth and Progenics Announce Preliminary Clinical Trial Results for Relistor Oral and Intravenous...

drugs.com
May 22, 2008
        

COLLEGEVILLE, Pa. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 22, 2008 - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced preliminary results from two clinical trials... ... COLLEGEVILLE, Pa. &...

                   

Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous...

redorbit.com
May 22, 2008
        

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR(TM) (methylnaltrexone bromide).

                   

Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous...

earthtimes.org
May 22, 2008
        

COLLEGEVILLE, Pa. & TARRYTOWN, N.Y. - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR